Table 3.

Randomized controlled trials – Trial design and results. Two values indicate tocilizumab; control group. HR, Hazard ratio; CI, confidence interval; CrI, credible interval; ARD, median absolute risk difference; OR, odds ratio; RR, rate ratio. MV, mechanical ventilation; HFO, high flow oxygen; NIV, noninvasive ventilation

	BACC	COVACTA	EMPACTA	CORIMUNO-TOCI	TOCIBRAS	RCT-TCZ-COVID-19	REMAP-CAP	RECOVERY
Study duration	28 days	60 days	60 days	28 days	29 days	30 days	21	28 days
Dose	8 mg/kg maximum 800 mg Single dose	8 mg/kg maximum 800 mg Single dose	8 mg/kg maximum 800 mg One or two doses	8 mg/kg Second dose of 400mg/kg at day 3 if notimproved	8mg/kg maximum 800 mg Single dose	8 mg/kg maximum 800 mg Two doses	8 mg/kg maximum 800 mg Second dose at physician discretion	400–800 mg (weight based) Second dose at physician discretion
Design	Double-blind placebo controlled	Double-blind placebo controlled	Double-blindplacebocontrolled	Open label	Open label	Open label	Open label Platform	Open label Platform
Primary outcome	Progression to intubation/death (HR 0.83, 95% CI 0.38–1.81)	Clinical status at day 28 (difference −1; 95% CI −2.5–0) Post hoc analysis-Clinical failure in those not in the ICU at baseline (HR 0.61, 95% CI 0.4–0.94)	MV or death at day 28 (HR 0.56, 95% CI 0.33–0.97)	Death/NIV/MV day 4 ARD −9%, 90% CrI; −21%-3% Survival without NIV/MV at day 14 (HR 0.58; 95% CrI 0.33–1)	Death/MV at day 15 OR 1.54 (95% CI 0.66–3.66)	Clinical worsening by day 14, RR 1.05; 95% CI 0.59–1.86	Number of organ support free days Adjusted OR 1.64, 95% CrI 1.25–2.14	Mortality RR 0.82, 95% CI 0.78–0.98
Primary outcome met	No	No	Yes	Yes (one of two)	No	No	Yes	Yes